Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia

被引：2
|
作者：
El Kinge, Abdul Rahman
Hatourn, Hassan A.
Mahfouz, Rami A. [2 ]
Otrock, Zaher K. [2 ]
Jabbour, Elias [3 ]
Kantarjian, Hagop [3 ]
Bazarbachi, Ali [1 ]
机构：
[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Bone Marrow Transplantat Program, Beirut, Lebanon
[2] Amer Univ Beirut, Med Ctr, Dept Pathol & Lab Med, Beirut, Lebanon
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷 / 04期
关键词：
ACUTE MYELOGENOUS LEUKEMIA; RELAPSE; CHEMOTHERAPY; PROPOSAL;
D O I：
10.1016/j.leukres.2008.05.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：565 / 566
页数：2
相关论文
共 50 条
  • [1] Post-remission therapy for acute myeloid leukemia
    Schlenk, Richard F.
    [J]. HAEMATOLOGICA, 2014, 99 (11) : 1663 - 1670
  • [2] Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
    Walter, Roland B.
    Medeiros, Bruno C.
    Powell, Bayard L.
    Schiffer, Charles A.
    Appelbaum, Frederick R.
    Estey, Elihu H.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (05): : 739 - 742
  • [3] Post-remission therapy of acute myeloid leukemia in first remission
    Kim, ST
    Kim, K
    Lee, SH
    Kim, WS
    Jung, CW
    Lee, MH
    Park, K
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 59 - 59
  • [4] Race and intensity of post-remission therapy in acute myeloid leukemia
    Brady, Anna K.
    Fu, Alex Z.
    Earl, Marc
    Kalaycio, Matt
    Advani, Anjali
    Saunthararajah, Yogen
    Sobecks, Ronald
    Copelan, Edward
    Sekeres, Mikkael A.
    [J]. LEUKEMIA RESEARCH, 2011, 35 (03) : 346 - 350
  • [5] Gemtuzumab ozogamicin in acute myeloid leukemia
    Godwin, C. D.
    Gale, R. P.
    Walter, R. B.
    [J]. LEUKEMIA, 2017, 31 (09) : 1855 - 1868
  • [6] Gemtuzumab ozogamicin for acute myeloid leukemia
    Appelbaum, Frederick R.
    Bernstein, Irwin D.
    [J]. BLOOD, 2017, 130 (22) : 2373 - 2376
  • [7] Gemtuzumab ozogamicin in acute myeloid leukemia
    C D Godwin
    R P Gale
    R B Walter
    [J]. Leukemia, 2017, 31 : 1855 - 1868
  • [8] Gemtuzumab Ozogamicin in Combination with Vorinostat and Azacitidine As Induction and Post-Remission Therapy in Older Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase 1 Study
    Walter, Roland B.
    Medeiros, Bruno C.
    Gardner, Kelda M.
    Estey, Elihu H.
    [J]. BLOOD, 2011, 118 (21) : 670 - 670
  • [9] PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML)
    Walter, B.
    Medeiros, B.
    Nielsen-Stoeck, M.
    Harrington, E.
    Powell, B.
    Schiffer, C.
    Appelbaum, F.
    Estey, E.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 29 - 30
  • [10] Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML).
    Brady, Anna K.
    Fu, Alex Z.
    Earl, Marc
    Kalaycio, Matt
    Advani, Anjali
    Saunthararajah, Yogen
    Sobecks, Ronald
    Copelan, Edward
    Sekeres, Mikkael A.
    [J]. BLOOD, 2009, 114 (22) : 419 - 419
12345